Safe and effective use of rivaroxaban for treatment of cancer-associated venous thromboembolic disease: a prospective cohort study

Low-molecular weight heparin (LMWH) has been the standard of care for treatment of venous thromboembolism (VTE) in patients with cancer. Rivaroxaban was approved in 2012 for the treatment of pulmonary embolism (PE) and deep vein thrombosis (DVT), but no prior studies have been reported specifically...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Thromb Thrombolysis
Main Authors: Mantha, Simon, Laube, Eva, Miao, Yimei, Sarasohn, Debra M., Parameswaran, Rekha, Stefanik, Samantha, Brar, Gagandeep, Samedy, Patrick, Wills, Jonathan, Harnicar, Stephen, Soff, Gerald A.
Format: Artigo
Jezik:Inglês
Izdano: Springer US 2016
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5318467/
https://ncbi.nlm.nih.gov/pubmed/27696084
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11239-016-1429-1
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki